Chemotherapy for acute myelogenous leukemia in children and adults: VAPA update
Chemotherapy for acute myelogenous leukemia in children and adults: VAPA update
复制标题
儿童和成人急性髓性白血病的化疗：VAPA 更新
DOI：
10.1182/blood.v62.2.315.bloodjournal622315
复制
发表时间：
1983
期刊：
影响因子：
20.3
通讯作者：
R. Gelber
中科院分区：
文献类型：
--
作者：
H. Weinstein;R. Mayer;D. Rosenthal;F. Coral;B. Camitta;R. Gelber
We designed a protocol (VAPA) that featured 14 mo of intensive postremission induction chemotherapy in an effort to improve remission durations for patients with acute myelogenous leukemia (AML). One hundred and seven patients under 50 yr of age were entered into this study. The rate of complete remission is 70%. A Kaplan-Meier analysis of patients entering remission predicts that 56% +/- 7% (+/-SE) of patients less than 18 yr and 45% +/- 9% of patients aged 18–50 yr will remain in remission at 3 yr (median follow-up is 43 mo). Patients with the monocytic subtype had a statistically significant shorter duration of remission (2-sided p less than 0.05). There was a high incidence of primary CNS relapse in children. Thirty-one of 41 patients who completed the regimen remain in remission without maintenance therapy. We conclude that the VAPA protocol continues to offer a promising approach to treatment of AML.
急性髓系白血病的强化化疗。
影响因子：
39.2
作者：
Gale,RP;Foon,KA;Cline,MJ;Zighelboim,J
通讯作者：
Zighelboim,J
影响因子：
20.3
作者：
K. Rai;J. Holland;O. Glidewell;V. Weinberg;K. Brunner;JP Obrecht;H. Preisler;IW Nawabi;D. Pr
通讯作者：
K. Rai;J. Holland;O. Glidewell;V. Weinberg;K. Brunner;JP Obrecht;H. Preisler;IW Nawabi;D. Pr
急性非淋巴细胞白血病的同种异体骨髓移植：一项试点研究。
影响因子：
20.3
作者：
Kersey,JH;Ramsay,NK;Kim,T;McGlave,P;Krivit,W;Levitt,S;Filipovich,A;Woods,W;O'Leary,M;Coccia,P;Nesbit,ME
通讯作者：
Nesbit,ME